Email this article 
Hide
Show all
Original Research
South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
Submitted: 11 March 2021 | Published: 31 May 2022
About the author(s)
Katherine E. Hodkinson, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and, Institution of National Health Laboratory Service, Johannesburg, South AfricaNikki Bouwer, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and, Institution of National Health Laboratory Service, Johannesburg, South Africa
Jenifer Vaughan, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and, Institution of National Health Laboratory Service, Johannesburg, South Africa
Abstract
Background: Chronic myeloid leukaemia (CML) is a haematological malignancy characterised by the translocation t(9;22)(q34;q11.2), resulting in a constitutively active tyrosine kinase. Globally, overall survival of blast crisis phase (BC) CML is one year. Newer tyrosine kinase inhibitors and allogeneic stem cell transplantation offer remission; however, refractory and relapsed disease remain the biggest challenges.
Objective: In South Africa, literature is lacking on BC-CML. This study aimed to determine the disease characteristics and overall survival in South Africa.
Methods: This retrospective, laboratory-based study reviewed all new BC-CML diagnoses via flow cytometry at Charlotte Maxeke Johannesburg Academic Hospital in Johannesburg, South Africa, between April 2016 and October 2019. BC-CML was defined as the presence of > 20% blasts with a CML history or the BCR-ABL1 fusion gene (p210/p190) in the appropriate clinical or pathological context. Survival outcomes were inferred from clinical and laboratory data.
Results: Twenty-two new cases of BC-CML were diagnosed (median age: 34 years). There were 20 (91%) cases with the fusion transcripts p210 and two (9%) cases with p190 BCRABL1. For blast lineage, 14 cases were myeloid (63.6%), six were lymphoid (27.3%), and two were ambiguous (9.1%). There was a 72.7% mortality (16 cases); sepsis, refractory and relapsed disease were the major causes. Patients who achieved remission had lower blast percentages, simple karyotypes, and a trend towards higher white cell and platelet counts at presentation.
Conclusion: Optimised management of early-stage CML, prevention and aggressive management of sepsis, with advocation for newer therapies are needed to improve the overall survival of BC-CML in South Africa.
Keywords
Metrics
Total abstract views: 3563Total article views: 5369
Crossref Citations
1. Blast crisis in chronic myeloid leukemia: An immunophenotypic analysis
Ak. Singh, An. Singh, S. Kanaujia, R. Kushwaha, U. S. Singh
International Journal of Science Annals vol: 5 issue: 1-2 first page: 31 year: 2022
doi: 10.26697/ijsa.2022.1-2.3
2. The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa
Siddeeq Hoosen, Irene Mackraj, Nadine Rapiti, Manishekhar Kumar
Advances in Hematology vol: 2023 first page: 1 year: 2023
doi: 10.1155/2023/2004135
3. Age- and gender-based frequency and association of common myeloproliferative mutations in a South African cohort
Bathabile Mbele, Kapila Bhowan, Brendon Roets
African Journal of Laboratory Medicine vol: 15 issue: 1 year: 2026
doi: 10.4102/AJLM.v15i1.2862
4. Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu‐Natal, South Africa
Caryn Benjamin, Stephanie Murugan, Siddeeq Hoosen, Nadine Rapiti
Health Science Reports vol: 6 issue: 7 year: 2023
doi: 10.1002/hsr2.1376